Physician profile
Lesley Angle
NPI 1437600350
$505.34
in general payments reported to CMS, 2019-2025
13 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $59.80 · 2024: $164 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.83 | 2022-2025 | |
| Vericel Corporation | $79.84 | 2022 | |
| Novo Nordisk INC | $63.56 | 2022-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $50.37 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $38.27 | 2022-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $37.84 | 2022-2025 | Shingrix, Arexvy |
| Genzyme Corporation | $35.13 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $25.00 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.37 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $15.97 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.80 | 2022 | |
| Merck Sharp & Dohme LLC | $13.74 | 2024 | M-M-R II, Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Angle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.